Optimal Difelikefalin Dose Reported for Pruritus in Hemodialysis
In a previous US phase 2 trial, no clear dose response was observed with difelikefalin.
Hemodialysis
FDA Warns of Potential Chemical Exposure With Certain Hemodialysis Machines
The source of the chemicals is from the silicone tubing used as a part of the hydraulics in the machine and the dialysate lines.
Apixaban Tied to Lower Risk for Recurrent VTE in Dialysis Population
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
Gene Polymorphism Might Influence Cinacalcet Response
A recent findings, if validated, may partly explain inter-individual differences in the response to cinacalcet treatment for secondary hyperparathyroidism.
High-Dose IV Iron Reduces Myocardial Infarction in Hemodialysis
Until now, no other treatment has been shown to reduce heart attack risk in patients on dialysis.
Sodium Polystyrene Sulfonate Ups Risk for Fatal Gastrointestinal Injury in HD
New data from DOPPS support previous studies finding higher risk for gastrointestinal injury after use of sodium polystyrene sulfonate.
Phosphate Binder Dissatisfaction May Affect Patient Outcomes
Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators.
Cinacalcet Does Not Up Risk for Severe Gastrointestinal Bleeding in Hemodialysis
Study is the largest to explore this potential safety issue to date.
FDA Wants Another Study Before Deciding on Tenapanor Approval
Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.
Tenapanor Reduces Phosphate Binder Pill Burden in Hemodialysis
Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.
